JP2004532894A5 - - Google Patents

Download PDF

Info

Publication number
JP2004532894A5
JP2004532894A5 JP2003503588A JP2003503588A JP2004532894A5 JP 2004532894 A5 JP2004532894 A5 JP 2004532894A5 JP 2003503588 A JP2003503588 A JP 2003503588A JP 2003503588 A JP2003503588 A JP 2003503588A JP 2004532894 A5 JP2004532894 A5 JP 2004532894A5
Authority
JP
Japan
Prior art keywords
amino
alkyl
methyl
methylsulfonyl
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003503588A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004532894A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/018845 external-priority patent/WO2002100818A2/en
Publication of JP2004532894A publication Critical patent/JP2004532894A/ja
Publication of JP2004532894A5 publication Critical patent/JP2004532894A5/ja
Pending legal-status Critical Current

Links

JP2003503588A 2001-06-13 2002-06-13 アルツハイマー病を治療するためのアミンジオール Pending JP2004532894A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29782701P 2001-06-13 2001-06-13
US33308401P 2001-11-19 2001-11-19
PCT/US2002/018845 WO2002100818A2 (en) 2001-06-13 2002-06-13 Aminediols as agents for the treatment of alzheimer's disease

Publications (2)

Publication Number Publication Date
JP2004532894A JP2004532894A (ja) 2004-10-28
JP2004532894A5 true JP2004532894A5 (https=) 2006-01-05

Family

ID=26970331

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003503588A Pending JP2004532894A (ja) 2001-06-13 2002-06-13 アルツハイマー病を治療するためのアミンジオール

Country Status (7)

Country Link
US (1) US6906104B2 (https=)
EP (1) EP1395251A2 (https=)
JP (1) JP2004532894A (https=)
AU (1) AU2002315131A1 (https=)
CA (1) CA2450205A1 (https=)
MX (1) MXPA03011521A (https=)
WO (1) WO2002100818A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6989276B2 (en) * 2001-05-10 2006-01-24 Battelle Energy Alliance, Llc Rapid classification of biological components
US7695919B2 (en) * 2001-05-10 2010-04-13 Battelle Energy Alliance, Llc Antibody profiling sensitivity through increased reporter antibody layering
USRE44031E1 (en) 2001-05-10 2013-02-26 Battelle Energy Alliance, Llc Antibody profiling sensitivity through increased reporter antibody layering
USRE46351E1 (en) 2001-05-10 2017-03-28 Battelle Energy Alliance, Llc Antibody profiling sensitivity through increased reporter antibody layering
CA2467798A1 (en) * 2001-11-19 2003-05-30 Pharmacia & Upjohn Company Amine 1,2- and 1,3-diol compounds and their use for treatment of alzheimer's disease
CN1732161A (zh) * 2002-09-06 2006-02-08 艾伦药物公司 1,3-二氨基-2-羟基丙烷前体药物衍生物
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
US7619059B2 (en) 2003-07-29 2009-11-17 Life Technologies Corporation Bimolecular optical probes
CA2445420A1 (en) 2003-07-29 2005-01-29 Invitrogen Corporation Kinase and phosphatase assays
US7727752B2 (en) * 2003-07-29 2010-06-01 Life Technologies Corporation Kinase and phosphatase assays
US20070196860A1 (en) * 2006-01-18 2007-08-23 Invitrogen Corporation Methods for Measuring Real Time Kinase Activity
US20080286881A1 (en) * 2007-05-14 2008-11-20 Apel William A Compositions and methods for combining report antibodies
US8351674B2 (en) * 2007-05-31 2013-01-08 Battelle Energy Alliance, Llc Image portion identification methods, image parsing methods, image parsing systems, and articles of manufacture
US8962677B2 (en) * 2007-07-12 2015-02-24 Acumen Pharmaceuticals, Inc. Methods of restoring cognitive ability using non-peptidic compounds
US9006283B2 (en) 2007-07-12 2015-04-14 Acumen Pharmaceuticals, Inc. Methods of modifying amyloid β oligomers using non-peptidic compounds
US20110098309A1 (en) * 2007-07-12 2011-04-28 Acumen Pharmaceuticals, Inc. Methods of inhibiting the formation of amyloid-beta diffusable ligands using acylhydrazide compounds
US20100286164A1 (en) * 2007-10-12 2010-11-11 The Brigham And Women's Hospital, Inc Substituted aryl alkylamino-oxy-analogs and uses thereof
WO2009079566A2 (en) 2007-12-18 2009-06-25 Acumen Pharmaceuticals, Inc. Novel addl receptor polypeptides, polynucleotides and host cells for recombinant production
US8969009B2 (en) * 2009-09-17 2015-03-03 Vicki S. Thompson Identification of discriminant proteins through antibody profiling, methods and apparatus for identifying an individual
US9410965B2 (en) * 2009-09-17 2016-08-09 Battelle Energy Alliance, Llc Identification of discriminant proteins through antibody profiling, methods and apparatus for identifying an individual
CN118047698A (zh) * 2024-01-30 2024-05-17 山东科巢生物制药有限公司 一种n-[(1r)-2-[1,1'-联苯]-4-基-1-(羟基甲基)乙基]氨基甲酸叔丁酯的制备方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5721131A (en) 1987-03-06 1998-02-24 United States Of America As Represented By The Secretary Of The Navy Surface modification of polymers with self-assembled monolayers that promote adhesion, outgrowth and differentiation of biological cells
US5912410A (en) 1990-06-15 1999-06-15 Scios Inc. Transgenic non-human mice displaying the amyloid-forming pathology of alzheimer's disease
US5387742A (en) 1990-06-15 1995-02-07 Scios Nova Inc. Transgenic mice displaying the amyloid-forming pathology of alzheimer's disease
WO1992013069A1 (en) 1991-01-21 1992-08-06 Imperial College Of Science, Technology & Medicine Test and model for alzheimer's disease
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
EP0620849B1 (en) 1992-01-07 2003-06-25 Elan Pharmaceuticals, Inc. Transgenic animal models for alzheimer's disease
US5604102A (en) 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
US5441870A (en) 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein
US5766846A (en) 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US5399763A (en) * 1993-02-01 1995-03-21 Nippon Kayaku Kabushiki Kaisha Process for preparing optically active 2-aminopropanal
NZ264143A (en) * 1993-08-09 1996-11-26 Lilly Co Eli Use of an aspartyl protease inhibitor to inhibit beta-amyloid peptide production
AU702293B2 (en) 1993-10-27 1999-02-18 Athena Neurosciences, Inc. Transgenic animals harboring APP allele having Swedish mutation
US5877399A (en) 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
US5728718A (en) * 1994-12-20 1998-03-17 The United States Of America As Represented By The Department Of Health And Human Services 2,5-diamino-3,4-disubstituted-1,6-diphenylhexane isosteres comprising benzamide, sulfonamide and anthranilamide subunits and methods of using same
US5744346A (en) 1995-06-07 1998-04-28 Athena Neurosciences, Inc. β-secretase
US5942400A (en) 1995-06-07 1999-08-24 Elan Pharmaceuticals, Inc. Assays for detecting β-secretase
US5763464A (en) * 1995-11-22 1998-06-09 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Retroviral agents containing anthranilamide, substituted benzamide and other subunits, and methods of using same
WO1998022597A2 (en) 1996-11-20 1998-05-28 Oklahoma Medical Research Foundation Cloning and characterization of napsin, an aspartic protease
US6191166B1 (en) 1997-11-21 2001-02-20 Elan Pharmaceuticals, Inc. Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis
US6045829A (en) 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
US5962506A (en) * 1997-07-07 1999-10-05 Pharmacopeia, Inc. Glycol and hydroxyphosphonate peptidomimetics as inhibitors of aspartyl proteases
GB9812189D0 (en) 1998-06-05 1998-08-05 Glaxo Group Ltd Methods and compositions for increasing penetration of HIV protease inhibitors
AU5002399A (en) 1998-07-17 2000-02-07 National Broach And Machine Company Full form roll finishing technique
CN1300320C (zh) 1998-09-24 2007-02-14 法玛西雅厄普约翰美国公司 阿尔茨海默氏疾病分泌酶
AU1727600A (en) * 1998-11-16 2000-06-05 C & D Technologies, Inc. Selectable capacity fixed footprint lead-acid battery racking system with horizontal plates
CN1390232A (zh) 1999-02-10 2003-01-08 艾兰制药公司 人β分泌酶、抑制剂、其组合物和用途
AU7757400A (en) 1999-08-09 2001-03-05 Vanderbilt University Antiviral therapy use of p-glycoprotein modulators
PT1224297E (pt) 1999-09-23 2009-08-17 Pharmacia & Upjohn Co Llc Secretase da doença de alzheimer, seus substratos app e suas utilizações
JP2002370183A (ja) * 2001-06-15 2002-12-24 Yamaha Motor Co Ltd 監視装置及び監視システム

Similar Documents

Publication Publication Date Title
JP2004532894A5 (https=)
JP2005534614A5 (https=)
JP2006501295A5 (https=)
RU2003134544A (ru) Амиды антраниловой кислоты, способы их получения, их применение в качестве антиаритмических средств, а также содержащие их фармацевтические композиции
RU2005107314A (ru) Пиримидопроизводные, характеризующиеся антипролиферативной активностью
ES2399314T3 (es) Gamma lactamas sustituidas como agentes terapeúticos
JP2004516314A5 (https=)
RU2002101723A (ru) Инданилзамещенные бензолкарбонамиды, способ их получения, их применение в качестве лекарственного средства, а также содержащие их фармацевтические композиции
RU2006107653A (ru) Связующее вспомогательное вещество и приготовленная на его основе таблетка в форме капли
RU2003121236A (ru) Арилированные амиды фуран- и тиофенкарбоновых кислот с блокирующим калиевый канал действием
JP2006501181A5 (https=)
RU2001113733A (ru) N-(2-арилпропионил) сульфонамиды и содержащие их фармацевтические препараты
JP2014502979A5 (https=)
JP2005533811A5 (https=)
RU2006124856A (ru) Гидронопольные производные в качестве агонистов по отношению к orl1 рецепторам человека
JP2006516626A5 (https=)
JPS6042374A (ja) 新規な1,5−ベンゾチアゼピン類、それらの製造方法およびそれらを含有している製薬学的組成物
HRP20130989T1 (hr) (2r) -2-[(4-sulfonil)aminofenil] propanamidi i farmaceutski sastavi koji ih sadrže
JP2010505869A5 (https=)
KR920000715A (ko) 신규의 n- 벤질-n1- 페닐-및- 펜알킬- 티오우레아류
IE40869L (en) Benzenesulphonyl ureas as hypoglycemic agents
JPH10251225A5 (https=)
ES2034484T3 (es) El uso de oxidos de tiadiazol para la preparacion de una composicion farmaceutica para el tratamiento de desordenes de motilidad gastrointestinal.
JP2003523995A5 (https=)
RU2004111284A (ru) Новое применение замещенных аминометилхроманов для лечения нарушений движений или нежелательных действий, вызываемых средствами, которые вводятся для лечения экстрапирамидных нарушений движений